Roivant Sciences (ROIV) Other Non Operating Income (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Other Non Operating Income came in at -$8.6 million in Q4 2025, down 8.67% YoY from -$9.4 million in Q4 2024, and down 50.33% on a QoQ basis from -$5.7 million in Q3 2025.
Roivant Sciences (ROIV) Other Non Operating Income (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Other Non Operating Income data on file, last reported at -$8.6 million in Q4 2025.
- Quarterly Other Non Operating Income fell 8.67% year-over-year to -$8.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$33.3 million (down 854.96% YoY) and the FY2026 annual result came in at $4.0 million, up 29.09% from the prior year.
- Other Non Operating Income slipped to -$8.6 million in Q4 2025, from -$5.7 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $18.1 million in Q4 2022 to a low of -$11.2 million in Q2 2025.
- A 5-year average of $577076.9 and a median of -$1.5 million in 2024 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income slumped 909.7% — and 2023, when it soared 523.32%.
- Tracing ROIV's Other Non Operating Income over 5 years: stood at $134000.0 in 2021, then soared by 13403.73% to $18.1 million in 2022, then decreased by 4.1% to $17.4 million in 2023, then sank by 145.39% to -$7.9 million in 2024, then slipped by 8.67% to -$8.6 million in 2025.
- The last three Other Non Operating Income figures came in at -$8.6 million (Q4 2025), -$5.7 million (Q3 2025), and -$11.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.13 Mn |
| Dec 31, 2025 | -8.56 Mn |
| Sep 30, 2025 | -5.69 Mn |
| Jun 30, 2025 | -11.21 Mn |
| Dec 31, 2024 | -7.88 Mn |
| Sep 30, 2024 | -1.45 Mn |
| Jun 30, 2024 | -3.61 Mn |
| Dec 31, 2023 | 17.35 Mn |
| Sep 30, 2023 | 12.76 Mn |
| Jun 30, 2023 | 4.59 Mn |
| Dec 31, 2022 | 18.10 Mn |
| Sep 30, 2022 | -5.95 Mn |
| Jun 30, 2022 | -1.09 Mn |
| Jun 30, 2021 | 134,000.00 |
| Dec 31, 2020 | 5.79 Mn |
| Sep 30, 2020 | 757,000.00 |
| Jun 30, 2020 | -2.84 Mn |